Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications.
Anal
HIV infection
High risk HPV
Men who have sex with men
Oral
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
28 May 2019
28 May 2019
Historique:
received:
24
01
2019
accepted:
17
05
2019
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
8
8
2019
Statut:
epublish
Résumé
Few studies focused on longitudinal modifications over time of high-risk HPV (HR-HPV) at anal and oral sites in HIV+ men who have sex with men (MSM). We described patterns and longitudinal changes of HR-HPV detection and the prevalence of HR-HPV covered by the nonavalent HPV vaccine (vax-HPV) at oral and anal sites in 165 HIV+ MSM followed in an Italian hospital. The samples were collected at baseline and after 24 months (follow-up). The presence of HPV was investigated with Inno-LiPA HPV Genotyping Extra II. Median age was 44 years (IQR 36-53), median CD4+ cell count at nadir was 312 cells/mm We believe that it is important testing multiple sites over time in HIV-positive MSM. ART seems to protect men from anal HR-HPV confirmed detection. Vaccination programmes could reduce the number of HR-HPV genotypes at anal site and the risk of the first HR-HPV acquisition at the oral site.
Sections du résumé
BACKGROUND
BACKGROUND
Few studies focused on longitudinal modifications over time of high-risk HPV (HR-HPV) at anal and oral sites in HIV+ men who have sex with men (MSM).
METHODS
METHODS
We described patterns and longitudinal changes of HR-HPV detection and the prevalence of HR-HPV covered by the nonavalent HPV vaccine (vax-HPV) at oral and anal sites in 165 HIV+ MSM followed in an Italian hospital. The samples were collected at baseline and after 24 months (follow-up). The presence of HPV was investigated with Inno-LiPA HPV Genotyping Extra II.
RESULTS
RESULTS
Median age was 44 years (IQR 36-53), median CD4+ cell count at nadir was 312 cells/mm
CONCLUSIONS
CONCLUSIONS
We believe that it is important testing multiple sites over time in HIV-positive MSM. ART seems to protect men from anal HR-HPV confirmed detection. Vaccination programmes could reduce the number of HR-HPV genotypes at anal site and the risk of the first HR-HPV acquisition at the oral site.
Identifiants
pubmed: 31138232
doi: 10.1186/s12889-019-7004-x
pii: 10.1186/s12889-019-7004-x
pmc: PMC6537447
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Pagination
645Références
Int J Cancer. 2009 Apr 1;124(7):1626-36
pubmed: 19115209
PLoS Pathog. 2010 Apr 08;6(4):e1000852
pubmed: 20386714
Lancet. 2011 Mar 12;377(9769):932-40
pubmed: 21367446
BMC Infect Dis. 2011 May 25;11:150
pubmed: 21612634
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):122-33
pubmed: 22045700
J Clin Invest. 2011 Dec;121(12):4593-9
pubmed: 22133884
J Infect Dis. 2012 Apr 15;205(8):1230-8
pubmed: 22438396
Sex Transm Dis. 2012 Jul;39(7):559-66
pubmed: 22706220
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
J Infect Dis. 2013 Jul 15;208(2):330-9
pubmed: 23596319
Virology. 2013 Nov;446(1-2):378-88
pubmed: 24074602
PLoS One. 2013 Nov 20;8(11):e79492
pubmed: 24278140
AIDS. 2013 Aug 24;27(13):2117-28
pubmed: 24384590
J Clin Microbiol. 2014 Jun;52(6):2206-9
pubmed: 24719435
AIDS Res Ther. 2014 Jul 29;11:21
pubmed: 25104966
BMC Public Health. 2015 May 02;15:453
pubmed: 25934423
AIDS. 2016 Jan 2;30(1):37-44
pubmed: 26355673
PLoS One. 2015 Oct 05;10(10):e0139524
pubmed: 26437318
EBioMedicine. 2015 Oct;2(10):1487-93
pubmed: 26629543
J Med Virol. 2016 Jul;88(7):1211-21
pubmed: 26636290
PLoS One. 2016 Jul 06;11(7):e0157976
pubmed: 27384050
Oncoimmunology. 2016 Jan 19;5(5):e1128612
pubmed: 27467943
J Glob Antimicrob Resist. 2013 Dec;1(4):201-206
pubmed: 27873613
Ann Clin Cytol Pathol. 2016;2(4):null
pubmed: 28042618
PLoS One. 2017 Feb 28;12(2):e0172964
pubmed: 28245234
J Infect Dis. 2017 Jun 15;215(12):1832-1835
pubmed: 28505338
J Glob Antimicrob Resist. 2017 Sep;10:106-112
pubmed: 28732792
PLoS One. 2017 Oct 31;12(10):e0186367
pubmed: 29088236
BMC Infect Dis. 2018 Jan 8;18(1):25
pubmed: 29310590
BMJ Open. 2018 Jan 27;8(1):e019894
pubmed: 29374678
J Infect Dis. 2018 Apr 23;217(10):1535-1543
pubmed: 29394362
Med Microbiol Immunol. 2018 Aug;207(3-4):183-194
pubmed: 29523966
Clin Infect Dis. 2019 Apr 8;68(8):1377-1387
pubmed: 30165551
J Infect Dis. 2019 Mar 15;219(7):1016-1025
pubmed: 30358875
PLoS Pathog. 2018 Nov 15;14(11):e1007357
pubmed: 30440043
BMC Infect Dis. 2018 Dec 19;18(1):683
pubmed: 30567494
J Infect Dis. 2019 May 5;219(11):1799-1803
pubmed: 30715452
Euro Surveill. 2019 Feb;24(7):null
pubmed: 30782268
Sex Transm Dis. 2019 Apr;46(4):229-233
pubmed: 30870323